2000-2021年孕产妇健康药物研发管线数据库分析:胎儿生长受限预防与治疗的新候选药物
该研究通过检索AdisInsight、PubMed及多个基金和临床试验数据库,建立了2000-2021年间针对五种妊娠相关疾病的候选药物数据库,其中胎儿生长受限候选药物63种,31种处于临床开发阶段,32种处于临床前阶段。阿司匹林、L-精氨酸和维生素D被列为具有高潜力的预防药物,而治疗性药物中无高潜力候选,仅5种评为中等潜力。作者认为L-精氨酸、阿司匹林和维生素D是有前景的高潜力预防药物,但基于现有管线,近期不太可能出现新的胎儿生长受限药物治疗。
要点
- 数据库共444种独特候选药物,其中63种针对胎儿生长受限。
- 31种处于临床开发阶段,32种处于临床前阶段。
- 阿司匹林、L-精氨酸和维生素D被评为高潜力预防药物。
核心结论
- L-精氨酸、阿司匹林和维生素D是有前景的高潜力胎儿生长受限预防药物。
- 基于现有药物管线,近期不太可能出现新的胎儿生长受限药物治疗药物。
研究设计与样本
- 研究类型为景观分析(landscape analysis),聚焦全球,尤其关注中低收入国家(LMICs)。
- 通过检索AdisInsight、PubMed及多个基金和临床试验数据库,建立2000-2021年间五种妊娠相关疾病的候选药物研发管线数据库。
- 样本为针对胎儿生长受限预防或治疗的药物、膳食补充剂和生物制品。
- 对临床和临床前候选药物进行描述性分析。
主要发现
- 数据库共纳入444种独特候选药物(涵盖所有五种妊娠相关疾病),其中63种针对胎儿生长受限。
- 63种胎儿生长受限候选药物中,31种处于临床开发阶段(I、II或III期),32种处于临床前开发阶段。
- 阿司匹林、L-精氨酸和维生素D被列为具有高潜力的预防药物。
- 无高潜力的胎儿生长受限治疗药物,但有5种被评为中等潜力:烯丙雌醇、达肝素、ω-3脂肪酸、他达拉非和联合国国际多种微量营养素产前补充剂(UNIMMAP)。
关键数值与推荐
- 候选药物根据预设标准(包括疗效、安全性和可及性)被评为高、中或低潜力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Accelerating Innovation for Mothers project established a new database of candidate medicines under development between 2000 and 2021 for five pregnancy-related conditions, including fetal growth restriction. The objective was to assess medicines for fetal growth restriction and their potential for clinical use globally. DESIGN: Landscape analysis. SETTING: Global (focus on low- and middle-income countries, LMICs). SAMPLE: Drugs, dietary supplements and biologics under investigation for prevention or treatment of fetal growth restriction. METHODS: A research pipeline database of medicines was created through searching AdisInsight, PubMed and various grant and clinical trial databases. Analysis of clinical and preclinical candidates were descriptive. MAIN OUTCOMES MEASURES: Fetal growth restriction candidates in clinical development were identified and ranked as high, medium or low potential based on prespecified criteria, including efficacy, safety and accessibility. RESULTS: Of the 444 unique candidates in the database across all five pregnancy-related conditions, 63 were for fetal growth restriction. Of these, 31 were in clinical development (phases I, II or III) and 32 were in preclinical development. Three candidates, aspirin, l-arginine and vitamin D, were ranked as having high potential as preventive agents. There were no high-potential candidates for treating fetal growth restriction, although five candidates were ranked as having medium potential: allylestrenol, dalteparin, omega-3 fatty acids, tadalafil, and United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP). CONCLUSIONS: l-Arginine, aspirin and vitamin D are promising, high-potential preventative agents for fetal growth restriction. Based on the medicines pipeline, new pharmacological agents for fetal growth restriction are unlikely to emerge in the near future.
引用
- Lim S, McDougall ARA, Goldstein M, et al. Analysis of a maternal health medicines pipeline database 2000-2021: New candidates for the prevention and treatment of fetal growth restriction. BJOG. 2023. PMID: 36655375. doi:10.1111/1471-0528.17392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。